MX2016016136A - Metodos para incrementar la inhibicion tonica y para tratar insomnio secundario. - Google Patents

Metodos para incrementar la inhibicion tonica y para tratar insomnio secundario.

Info

Publication number
MX2016016136A
MX2016016136A MX2016016136A MX2016016136A MX2016016136A MX 2016016136 A MX2016016136 A MX 2016016136A MX 2016016136 A MX2016016136 A MX 2016016136A MX 2016016136 A MX2016016136 A MX 2016016136A MX 2016016136 A MX2016016136 A MX 2016016136A
Authority
MX
Mexico
Prior art keywords
sleep
subject
increase
methods
reduce
Prior art date
Application number
MX2016016136A
Other languages
English (en)
Inventor
During Matthew
Original Assignee
Ovid Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ovid Therapeutics Inc filed Critical Ovid Therapeutics Inc
Publication of MX2016016136A publication Critical patent/MX2016016136A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Steroid Compounds (AREA)

Abstract

Se describen métodos para incrementar la inhibición tónica en un sujeto en necesidad del mismo, por ejemplo, un sujeto con el síndrome Fragile X o el síndrome de Angelman. Los métodos para tratar insomnio secundario en un sujeto con un trastorno o desorden neurodegenerativo, también se describen. Los métodos pueden incluir administrar al sujeto una cantidad efectiva de 4,5,6,7-tetrahidroisoxazolo(5,4-c)piridina-3-ol (THIP) o un derivado de la misma, una sal farmacéuticamente aceptable de la misma, incrementar la inhibición tónica en neuronas del sujeto, para incrementar el sueño de onda lenta (SWS), y/o la actividad de onda lenta (SWA), normalizar la arquitectura del sueño, reducir el insomnio secundario, incrementar el sueño paradójico (NREM), incrementar la continuidad del sueño, mejorar la actividad delta dentro de NREM, incrementar o mejorar el tiempo total del sueño (TST), incrementar o mejorar la eficiencia del sueño, reducir el tiempo total despierto (TAA), reducir el número de despertamientos (NWA), reducir la latencia del sueño persistente (LPS) o reducir los despertamiento después de conciliar el sueño (WASO) en el sujeto, o cualquier combinación de los mismos.
MX2016016136A 2014-06-06 2015-06-03 Metodos para incrementar la inhibicion tonica y para tratar insomnio secundario. MX2016016136A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462008939P 2014-06-06 2014-06-06
PCT/US2015/034018 WO2015187851A1 (en) 2014-06-06 2015-06-03 Methods of increasing tonic inhibition and treating secondary insomnia

Publications (1)

Publication Number Publication Date
MX2016016136A true MX2016016136A (es) 2017-07-05

Family

ID=54767324

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2020012404A MX2020012404A (es) 2014-06-06 2015-06-03 Metodos para incrementar la inhibicion tonica y para tratar insomnio secundario.
MX2016016136A MX2016016136A (es) 2014-06-06 2015-06-03 Metodos para incrementar la inhibicion tonica y para tratar insomnio secundario.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2020012404A MX2020012404A (es) 2014-06-06 2015-06-03 Metodos para incrementar la inhibicion tonica y para tratar insomnio secundario.

Country Status (19)

Country Link
US (10) US20150352085A1 (es)
EP (3) EP3151832B1 (es)
JP (4) JP2017516868A (es)
AR (1) AR100772A1 (es)
AU (4) AU2015269667B2 (es)
CA (1) CA2950845C (es)
CY (2) CY1124368T1 (es)
DK (2) DK3151832T3 (es)
ES (2) ES2876350T3 (es)
HR (2) HRP20210902T1 (es)
HU (2) HUE055400T2 (es)
IL (2) IL249287B (es)
LT (2) LT3151832T (es)
MX (2) MX2020012404A (es)
PL (2) PL3372229T3 (es)
PT (2) PT3372229T (es)
RS (2) RS62007B1 (es)
SI (2) SI3372229T1 (es)
WO (1) WO2015187851A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2020012404A (es) * 2014-06-06 2022-04-11 Ovid Therapeutics Inc Metodos para incrementar la inhibicion tonica y para tratar insomnio secundario.
US10080898B2 (en) * 2015-05-29 2018-09-25 Medtronic, Inc. Simultaneous physiological sensing and stimulation with saturation detection
US10434308B2 (en) 2015-05-29 2019-10-08 Medtronic, Inc. Impedance matching and electrode conditioning in patient interface systems
CN116531370A (zh) * 2015-07-17 2023-08-04 奥维德医疗公司 用加波沙朵治疗发育障碍的方法
US9682069B2 (en) 2015-07-17 2017-06-20 Ovid Therapeutics Inc Methods of treating Dravet syndrome
WO2018017639A1 (en) * 2016-07-19 2018-01-25 Georgia State University Research Foundation Methods for treating rett syndrome
WO2018031748A1 (en) 2016-08-11 2018-02-15 Ovid Therapeutics Inc. Methods and compositions for treatment of epileptic disorders
JP2019535760A (ja) * 2016-11-22 2019-12-12 オービッド・セラピューティクス・インコーポレイテッドＯｖｉｄ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． フルピルチンを用いた発達障害および／または発作性障害の処置方法
US10071083B2 (en) * 2017-02-03 2018-09-11 Ovid Therapeutics Inc Use of gaboxadol in the treatment of tinnitus
US20180338959A1 (en) * 2017-05-24 2018-11-29 Ovid Therapeutics Inc. Treatment of depressive disorders
CA3071939A1 (en) 2017-08-04 2019-02-07 Ovid Therapeutics Inc. Use of gaboxadol in the treatment of diabetes and related conditions
US11181384B2 (en) * 2018-07-23 2021-11-23 Waymo Llc Verifying map data using challenge questions
JP2022501384A (ja) 2018-09-20 2022-01-06 オービッド・セラピューティクス・インコーポレイテッドOvid Therapeutics Inc. トゥレット症候群、チックおよび吃音の処置のためのガボキサドールの使用
GB2594616A (en) 2018-11-21 2021-11-03 Certego Therapeutics Inc Gaboxadol for reducing risk of suicide and rapid relief of depression
US11690829B2 (en) 2018-12-17 2023-07-04 Ovid Therapeutics Inc. Use of gaboxadol for the treatment of non-24 hour sleep-wake disorder
US11786694B2 (en) 2019-05-24 2023-10-17 NeuroLight, Inc. Device, method, and app for facilitating sleep
CA3146737A1 (en) * 2019-07-15 2021-01-21 Ovid Therapeutics Inc. Pharmaceutical formulations containing gaboxadol for therapeutic treatment
CN114786669A (zh) * 2019-12-18 2022-07-22 奥维德医疗公司 用于1p36缺失综合征的治疗性治疗的加波沙朵
CN116267014A (zh) 2020-05-20 2023-06-20 Certego治疗公司 环状氘化加波沙朵及其用于治疗精神障碍的用途

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK270378A (da) 1977-06-20 1978-12-21 Krogsgaard Larsen P Isoxazolderivater
US4362731A (en) 1980-09-01 1982-12-07 Sandoz Ltd. Myotonolytic use of 4,5,6,7-tetrahydroisoxazolo [5,4-c] pyridin-3-ol and derivatives thereof
US4353910A (en) 1981-11-27 1982-10-12 Kefalas A/S Derivatives of 4,5,6,7-tetrahydroisoxazolo [5,4-c] pyridine-3-one, pharmaceutical compositions and methods of treatment
DE19525598C2 (de) 1995-07-13 1997-09-25 Max Planck Gesellschaft Schlafmittel
DE19526864A1 (de) 1995-07-22 1997-01-23 Labtec Gmbh Hormonpflaster
US6461644B1 (en) 1996-03-25 2002-10-08 Richard R. Jackson Anesthetizing plastics, drug delivery plastics, and related medical products, systems and methods
US5948433A (en) 1997-08-21 1999-09-07 Bertek, Inc. Transdermal patch
US6676961B1 (en) 2002-03-06 2004-01-13 Automated Carrier Technologies, Inc. Transdermal patch assembly
US20050137222A1 (en) * 2003-12-18 2005-06-23 H. Lundbeck A/S Treatment of insomnia in human patients
JP2007530604A (ja) 2004-04-02 2007-11-01 ハー・ルンドベック・アクチエゼルスカベット 呼吸機能障害の治療
DE102005020882A1 (de) * 2005-05-04 2006-11-09 Dömling, Alexander, Dr. Verwendung von Gaboxadol und Derivaten zur Behandlung von Kinase-induzierten Krankheiten
US20110046090A1 (en) * 2005-10-31 2011-02-24 Braincells Inc. Modulation of neurogenesis with gaba agents and gaba analogs
US20090143335A1 (en) 2007-10-29 2009-06-04 H. Lundbeck A/S Modified absorption formulation of gaboxadol
CA2705733C (en) 2007-11-13 2015-02-03 Cadence Pharmaceuticals Reduced dose intravenous acetaminophen
EP2334299A1 (en) * 2008-09-01 2011-06-22 H. Lundbeck A/S Pharmaceutical composition comprising gaboxadol and an inhibitor of patl or oat
MX2020012404A (es) 2014-06-06 2022-04-11 Ovid Therapeutics Inc Metodos para incrementar la inhibicion tonica y para tratar insomnio secundario.
CN116531370A (zh) * 2015-07-17 2023-08-04 奥维德医疗公司 用加波沙朵治疗发育障碍的方法
US9399034B1 (en) 2015-08-11 2016-07-26 Ovid Therapeutics Inc Methods of sedation during critical care treatment

Also Published As

Publication number Publication date
US20170071917A1 (en) 2017-03-16
US20230051859A1 (en) 2023-02-16
JP2017516868A (ja) 2017-06-22
PT3151832T (pt) 2021-06-15
EP3372229A1 (en) 2018-09-12
ES2876350T3 (es) 2021-11-12
IL268960A (en) 2019-10-31
US9801864B2 (en) 2017-10-31
HRP20210901T1 (hr) 2021-09-17
AU2015269667A1 (en) 2016-12-22
AU2015269667B2 (en) 2020-07-30
US20170087133A1 (en) 2017-03-30
US11278529B2 (en) 2022-03-22
EP3151832A1 (en) 2017-04-12
MX2020012404A (es) 2022-04-11
CY1124366T1 (el) 2022-07-22
DK3372229T3 (da) 2021-06-14
JP2021178836A (ja) 2021-11-18
LT3372229T (lt) 2021-07-12
AU2022200085A1 (en) 2022-02-03
AU2020217342A1 (en) 2020-08-27
HRP20210902T1 (hr) 2021-09-17
US9446028B2 (en) 2016-09-20
US9744159B2 (en) 2017-08-29
RS62007B1 (sr) 2021-07-30
PL3151832T3 (pl) 2021-10-25
AU2020217342B2 (en) 2021-10-07
EP3795156A1 (en) 2021-03-24
AU2024202604A1 (en) 2024-05-09
US20160038469A1 (en) 2016-02-11
IL268960B (en) 2021-05-31
HUE055400T2 (hu) 2021-11-29
SI3151832T1 (sl) 2021-08-31
RS62006B1 (sr) 2021-07-30
ES2875742T3 (es) 2021-11-11
CA2950845C (en) 2023-04-25
WO2015187851A1 (en) 2015-12-10
US20170273956A1 (en) 2017-09-28
EP3372229B1 (en) 2021-03-24
EP3151832B1 (en) 2021-03-24
US9339495B2 (en) 2016-05-17
US20180015076A1 (en) 2018-01-18
PL3372229T3 (pl) 2021-10-04
CY1124368T1 (el) 2022-07-22
PT3372229T (pt) 2021-06-17
HUE055155T2 (hu) 2021-11-29
EP3151832A4 (en) 2018-01-17
JP2023123442A (ja) 2023-09-05
SI3372229T1 (sl) 2021-09-30
LT3151832T (lt) 2021-07-12
DK3151832T3 (da) 2021-06-14
US20220016091A1 (en) 2022-01-20
US20150352085A1 (en) 2015-12-10
IL249287A0 (en) 2017-02-28
US20180303805A1 (en) 2018-10-25
AR100772A1 (es) 2016-11-02
JP2020063264A (ja) 2020-04-23
US20160228418A1 (en) 2016-08-11
IL249287B (en) 2021-03-25
CA2950845A1 (en) 2015-12-10

Similar Documents

Publication Publication Date Title
MX2016016136A (es) Metodos para incrementar la inhibicion tonica y para tratar insomnio secundario.
EA201890059A1 (ru) Ингибиторы hpk1 и способы их применения
UY36308A (es) Inhibidores de histona acetiltransferasas espirocíclicas (hat) y métodos para su uso
MX2021000148A (es) Inhibidores eterociclicos de erk1 y erk2 y su uso en el tratamiento del cancer.
MX2015016983A (es) Moduladores del transporte nuclear y usos de los mismos.
WO2015112793A3 (en) Methods of expanding ex vivo natural killer t (nkt) cells and therapeutic uses thereof
EA201690093A1 (ru) Производные пирроло[3,2-d]пиримидина для лечения вирусных инфекций и других заболеваний
WO2015123423A3 (en) Methods for treating patients with hypercholesterolemia that is not adequately controlled by moderate-dose statin therapy
EA201591290A3 (ru) Креноланиб для лечения пролиферативных расстройств, связанных с мутацией flt3
EA201690212A8 (ru) Способы лечения или профилактики офтальмологических патологических состояний
WO2014141110A3 (en) Aminonitriles as kynurenine pathway inhibitors
MX2021002321A (es) Nuevos metodos.
MX2019014410A (es) Metodos de tratamiento de pacientes con enfermedad de fabry que tienen insuficiencia renal.
NZ606903A (en) Methods for the treatment or prophylaxis of thrombosis or embolism
WO2015085909A8 (zh) 一种具有腺苷受体拮抗活性的氨基嘧啶杂环化合物
RU2018135973A (ru) Фармацевтическая комбинация, содержащая метроформин и дигидрокверценин, и ее применение для лечения рака
EA032955B3 (ru) Применение производного глутаримида для лечения эозинофильных заболеваний
PH12014500990A1 (en) Methods for treating gout flares
WO2016029136A8 (en) 3-amidobenzamides and uses thereof for increasing cellular levels of a3g
MX2017012926A (es) Inhibidores y sus usos.
AR095594A1 (es) Métodos para tratar infecciones en pacientes con sobrepeso y obesos usando antibióticos
MX2013014398A (es) Derivados de sulfonamida heterociclicos.
WO2014127232A3 (en) Methods for maintaining population of therapeutic cells in treatment site of subject in need of cell therapy
WO2016106357A8 (en) Combination of raf inhibitors and aurora kinase inhibitors
SG10201809673RA (en) Treatment of androgen deprivation therapy associated symptoms